tradingkey.logo

Basel Medical Group Ltd

BMGL
0.651USD
+0.026+4.09%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
12.23MMarktkapitalisierung
VerlustKGV TTM

Basel Medical Group Ltd

0.651
+0.026+4.09%

mehr Informationen über Basel Medical Group Ltd Unternehmen

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care.

Basel Medical Group Ltd Informationen

BörsenkürzelBMGL
Name des UnternehmensBasel Medical Group Ltd
IPO-datumFeb 25, 2025
CEOChhoa (Yen Feng)
Anzahl der mitarbeiter77
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 25
Addresse600 North Bridge Road, #12-02/03
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandSingapore
Postleitzahl188778
Telefon6562919188
Websitehttps://www.baselmedical.com
BörsenkürzelBMGL
IPO-datumFeb 25, 2025
CEOChhoa (Yen Feng)

Führungskräfte von Basel Medical Group Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jianing Lu
Ms. Jianing Lu
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Yen Feng (Darren) Chhoa, M.D.
Dr. Yen Feng (Darren) Chhoa, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Paul D. Freudenthaler, CPA
Mr. Paul D. Freudenthaler, CPA
Independent Director
Independent Director
--
--
Mr. Tony Chen
Mr. Tony Chen
Independent Director
Independent Director
--
--
Mr. Kwek Yoon Soong
Mr. Kwek Yoon Soong
Independent Director
Independent Director
--
--
Mr. Boon Chye Tan
Mr. Boon Chye Tan
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Keng Leong (Raymond) Fung
Mr. Keng Leong (Raymond) Fung
Chairman of the Board
Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jianing Lu
Ms. Jianing Lu
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Yen Feng (Darren) Chhoa, M.D.
Dr. Yen Feng (Darren) Chhoa, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Paul D. Freudenthaler, CPA
Mr. Paul D. Freudenthaler, CPA
Independent Director
Independent Director
--
--
Mr. Tony Chen
Mr. Tony Chen
Independent Director
Independent Director
--
--
Mr. Kwek Yoon Soong
Mr. Kwek Yoon Soong
Independent Director
Independent Director
--
--
Mr. Boon Chye Tan
Mr. Boon Chye Tan
Chief Commercial Officer
Chief Commercial Officer
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, Feb 5
Aktualisiert: Thu, Feb 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Rainforest Capital VCC
54.32%
Citadel Advisors LLC
0.49%
Morgan Stanley & Co. LLC
0.40%
Marex Group plc
0.31%
Virtu Americas LLC
0.18%
Andere
44.29%
Aktionäre
Aktionäre
Anteil
Rainforest Capital VCC
54.32%
Citadel Advisors LLC
0.49%
Morgan Stanley & Co. LLC
0.40%
Marex Group plc
0.31%
Virtu Americas LLC
0.18%
Andere
44.29%
Aktionärstypen
Aktionäre
Anteil
Corporation
54.32%
Investment Advisor
0.66%
Research Firm
0.58%
Hedge Fund
0.49%
Investment Advisor/Hedge Fund
0.04%
Andere
43.91%

Institutionelle Beteiligung

Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
14
296.50K
0.70%
--
2025Q3
14
296.50K
0.70%
+165.18K
2025Q2
6
124.34K
0.00%
+124.34K
2025Q1
5
12.74M
67.81%
+12.74M

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Rainforest Capital VCC
10.21M
54.32%
+30.65K
+0.30%
Nov 17, 2025
Citadel Advisors LLC
93.00K
0.49%
+93.00K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
74.29K
0.4%
+74.29K
--
Sep 30, 2025
Marex Group plc
58.91K
0.31%
+44.99K
+323.10%
Sep 30, 2025
Virtu Americas LLC
33.79K
0.18%
+17.61K
+108.84%
Sep 30, 2025
Vanguard Personalized Indexing Management, LLC
22.11K
0.12%
+22.11K
--
Sep 30, 2025
UBS Financial Services, Inc.
5.90K
0.03%
+255.00
+4.52%
Sep 30, 2025
Geode Capital Management, L.L.C.
6.97K
0.04%
--
--
Nov 30, 2025
Bell Investment Advisors, Inc.
248.00
0%
+248.00
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI